TP53 and cancer: Given the unique feature of accumulation and GOF of mutp53 and the high mutational frequency of p53 in human cancers, targeting mutp53 for degradation in cancer cells has been actively tested as an attractive strategy that specifically targets cancer cells carrying mutp53 with minimal side effects on normal cells, which is urgently needed in cancer therapies3,6,7.